ArticleGland surgery2025
Prognostic factors for survival and recurrence in papillary thyroid carcinoma: a retrospective study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic impact of the lipid metabolism gene AGPAT4 in the tumor immune microenvironment of thyroid cancer.Genomics & informatics · 2026Article
- Predictive value of preoperative serum thyroglobulin and anti-thyroglobulin antibodies for central compartment lymph node metastasis in cN0 papillary thyroid carcinoma.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) accounts for 80-85% of cases and generally has an excellent prognosis. However, outcomes vary with clinicopathological factors, and identifying prognostic indicators is clinically important for tailoring treatment strategies and long-term follow-up. Regional data on prognostic factors in PTC remain limited. This study investigates the impact of patient and tumor characteristics on survival and recurrence outcomes at a single institution. Methods: A retrospective cohort study included patients aged 18 years or older diagnosed with PTC between January 2015 and September 2023 at a secondary hospital in Riyadh, Saudi Arabia. Eligible patients had confirmed PTC with sufficient clinical records and no prior thyroid cancer treatment. The data collected included demographics, comorbidities, risk factors, baseline clinical and laboratory factors, and tumor pathology [tumor, node, metastasis (TNM) stage and variants]. Treatment details and follow-up outcomes were reviewed through electronic medical records. Patients were followed for a median of 5.45 years to assess survival, recurrence, and postoperative complications. Associations between clinical characteristics and prognostic outcomes were analyzed using Chi-squared and Fisher tests. Results: A total of 293 patients were included (mean age at diagnosis 41.7±12.2 years); 82.2% were female. Most patients (79.1%) presented with early-stage disease, and 62.3% had the classic variant of the disease. The overall 10-year survival rate was 95.8%, and recurrence occurred in 2.1%. Patients over 50 years had more significant comorbidities than those aged 18 to 50 years, such as diabetes mellitus (P=0.001, 37.8% Conclusions: Patients with PTC in this Saudi cohort demonstrated excellent long-term outcomes, characterized by high survival rates and low recurrence rates. Older age and male sex were associated with more aggressive disease features, yet with appropriate management, outcomes remained favorable. These findings emphasize the importance of comprehensive risk assessment and reinforce the effectiveness of current treatment strategies, providing region-specific evidence to inform clinical guidelines and optimize long-term patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.